PL-3994 reduces cardiac hypertrophy in heart failure study
29 September 2015 | By Victoria White
Preclinical data showed that treatment with PL-3994 significantly reduced cardiac hypertrophy and pro-fibrotic and inflammatory gene activation...
List view / Grid view
News
LDC and Infinity to work together on oncology drug discovery
29 September 2015 | By Victoria White
LDC and Infinity will work together to select high-potential cancer drug discovery projects from the LDC’s portfolio and its broad academic network...
New CRISPR system could change the scientific landscape
28 September 2015 | By Victoria White
The newly described Cpf1 system differs in several important ways from Cas9, with significant implications for research and therapeutics...
Heptares gets grant to develop cocaine addiction treatment
28 September 2015 | By Victoria White
The $5.5 million grant will support a three-year research project aimed at developing a selective antagonist for the human Orexin-1 receptor...
H7N9 influenza vaccine failure due to “immune camouflage”
28 September 2015 | By Victoria White
H7N9 candidate vaccines have failed to elicit a strong immune response necessary to protect from infection. A study has revealed that it may be due to immune camouflage...
Protectimmun and ICL team up for preclinical asthma research
28 September 2015 | By Victoria White
The research agreement, facilitated by Johnson & Johnson Innovation, will fund preclinical research with a drug candidate in a proof-of-concept disease model of allergic asthma...
BMS and Moffitt form immuno-oncology partnership
25 September 2015 | By Victoria White
Bristol-Myers Squibb and Moffitt will conduct a range of early phase clinical studies, including clinical investigations by young investigators to strengthen their development as clinical research scientists...
MedImmune and 3M partner to develop novel TLR agonist cancer therapies
25 September 2015 | By Victoria White
TLR agonists are promising agents that activate innate immune cells and enhance the visibility of cancer tumours...
Study highlights the potential of FAK inhibition in fighting cancer
25 September 2015 | By Victoria White
Researchers discovered that FAK inhibition can modulate the balance of immune cells in a tumour enabling an immune response to destroy the cancer cells...
TSRI awarded $6 million to develop HIV/AIDS vaccine, eCD4-lg
25 September 2015 | By Victoria White
When eCD4-lg was tested in animal models, the results were so powerful and effective that they suggested the compound’s potential to serve the role of an alternative HIV/AIDS vaccine...
New collaboration to interpret human proteome information
25 September 2015 | By Victoria White
The team of researchers will comprehensively study human proteomes with the aim of turning the vast amount of molecular information into designs for new reagents, equipment, workflows, assays and software...
Regeneron and ETI team up to discover monoclonal antibodies
24 September 2015 | By Victoria White
Regeneron will provide the ETI with access to VelocImmune technology to generate antibodies against targets of interest and explore potential therapeutic applications for human disease...
MRC Technology & University of Lausanne collaborate on MALT1 inhibitors
24 September 2015 | By Victoria White
Disregulation of MALT1 is associated with some subsets of lymphoma suggesting that MALT1 could be a promising drug target for these types of cancer...
MISSION Therapeutics receives funding for DUB cancer programme
24 September 2015 | By Victoria White
Deubiquitylating enzymes (DUBs) are involved in multiple cellular processes, including DNA damage and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs...
Smart robot accelerates cancer treatment research
23 September 2015 | By Victoria White
The new smart research robot, developed at Uppsala University, accelerates research on cancer treatments by finding optimal treatment combinations...